

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**康宁杰瑞**

ALPHAMAB ONCOLOGY

**ALPHAMAB ONCOLOGY**

**康寧傑瑞生物製藥**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9966)**

## **INSIDE INFORMATION ANNOUNCEMENT**

### **COLLABORATION WITH CSPC IN RELATION TO THE DEVELOPMENT AND COMMERCIALIZATION OF JSKN003 IN MAINLAND CHINA**

This announcement is made by Alphamab Oncology (the “**Company**”) pursuant to Rule 13.09(2) (a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the inside information provision (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) is pleased to announce that on September 29, 2024, Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (江蘇康寧傑瑞生物製藥有限公司) (“**Alphamab**”), a wholly-owned subsidiary of the Company, entered into a licensing agreement (the “**Licensing Agreement**”) with Shanghai JMT-Bio Technology Co., Ltd. (上海津曼特生物科技有限公司) (“**JMT-Bio**”), a wholly-owned subsidiary of CSPC Pharmaceutical Group Limited (“**CSPC**”), the shares of which are listed on the Stock Exchange (stock code: 1093), to develop, sell, offer for sale and commercialize JSKN003 (a biparatopic HER2-targeting antibody-drug conjugate (“**ADC**”)), for the treatment of tumor-related indications (the “**Field**”) in mainland China (excluding Hong Kong, Macau or Taiwan) (the “**Territory**”).

According to the terms of the Licensing Agreement, JMT-Bio will obtain the exclusive license and sublicense rights to develop, sell, offer for sale and commercialize JSKN003 and become the sole marketing authorization holder for JSKN003 for the Field in the Territory. JMT-Bio shall bear at its own costs and expenses for the clinical development activities under the Licensing Agreement. Alphamab will retain the sole right to supply JSKN003 for any purpose(s) within or outside the Territory.

According to the Licensing Agreement, the Company is entitled to receive upfront payment and milestone payments of up to RMB3.08 billion in total, including an upfront payment of RMB400 million, a development milestone payment of RMB300 million related to enrollment of the first patient for multiple registration trials, and regulatory milestone payments based on regulatory approval progress and commercial milestones payments. In addition, the Company is also entitled to receive a double-digit percentage of royalties on net product sales of JSKN003.

The Company believes that entering into the License Agreement is in the best interests of the Company and its shareholders as a whole.

To the best knowledge and belief of the Company, JMT-Bio is not a connected person (as defined in the Listing Rules) of the Company. The transactions contemplated under the Licensing Agreement do not constitute any notifiable transaction or connected transaction of the Company under the Listing Rules.

**Cautionary Statement required by Rule 18A.05 of the Listing Rules:** The Company cannot guarantee that it will be able to develop and/or ultimately market JSKN003 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

### **ABOUT JSKN003**

JSKN003 is a biparatopic HER2-targeting ADC, of which a topoisomerase I inhibitor is linked to the N-glycosylation site of the antibody KN026 (a recombinant humanized anti-HER2 bispecific antibody) via the glycosite-specific conjugation. The click reaction-based conjugation confers better serum stability than maleimide-Michael reaction-based conjugation. The biparatopic HER2 targeting enables JSKN003 to have a stronger internalization induction and bystander killing effect, leading to potent anti-tumor activity in HER2 expression tumors. Currently, a phase I clinical study in Australia, phase I/II and phase III clinical studies in China of JSKN003 are undergoing.

### **ABOUT JMT-BIO AND CSPC**

JMT-Bio is a wholly-owned subsidiary of CSPC, which is a national innovative company with strong capabilities in research and development, manufacturing and marketing innovative drugs. CPSC, listed on the Stock Exchange (stock code: 1093), was selected as a constituent stock of the Hang Sang Index in 2018 and was the first constituent stock in the pharmaceutical sector since the launch of the index. Currently, it is one of constituent stocks of Hang Seng Composite Index, Hang Seng Healthcare Index, Hang Seng Mainland Healthcare Index, Hang Seng Stock Connect Index, Hang Seng (Hong Kong-listed) 100 Index and Hang Seng China Enterprise Index. As of the date of this announcement, CPSC has total assets of more than RMB30 billion and more than 23,000 employees. CSPC has a national top research and development team with research and development bases in Shijiazhuang, Shanghai, Beijing and the United States, focusing on the discovery, research and development of small molecule targeted drugs, nano-drugs, monoclonal antibody drugs, bispecific antibody drugs, ADCs and biological drugs in the immune field.

## **ABOUT THE COMPANY**

The Company is a leading biopharmaceutical company in China with a fully integrated proprietary technology platform in bispecific antibodies, multifunctional protein engineering and ADC. The Company's highly differentiated in-house pipeline consists of monoclonal antibodies, bispecific antibodies, and ADCs in staggered development status in oncology, including, among others, one approved for marketing by the National Medical Products Administration of China (國家藥品監督管理局) and three in late clinical stage. The Company has developed various technologies and platforms of antibody-based therapies for oncology treatment and expertise in this regard. Benefitting from the proprietary protein engineering platforms and structure-guided molecular modeling expertise, the Company is able to create a new generation of multi-functional biological drug candidates that could potentially benefit patients globally.

By Order of the Board  
**Alphamab Oncology**  
**Dr. XU Ting**  
*Chairman and Executive Director*

Hong Kong, September 29, 2024

*As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, and Dr. GUO Zijian, Mr. WEI Kevin Cheng and Mr. WU Dong as independent non-executive Directors.*